Age related changes in brain metabolites observed by 1H MRS in APP/PS1 mice

Neurobiology of Aging

Volumn 29, Issue 9, 2008, Pages 1423-1433

  Oberg, Johanna ^a   Spenger, Christian ^a   Wang, Fu Hua ^b   Andersson, Anders ^b   Westman, Eric ^a   Skoglund, Peter ^a   Sunnemark, Dan ^b   Norinder, Ulf ^b   Klason, Tomas ^b   Wahlund, Lars Olof ^a   Lindberg, Mattias ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

Alzheimer's disease; Amyloid; APP PS1; Magnetic resonance spectroscopy (MRS); Multivariate data analysis; PLS DA; Presenilin; Spectroscopy

Indexed keywords

AMYLOID PRECURSOR PROTEIN; GLUTAMIC ACID; GUANIDINOACETIC ACID; INOSITOL; LIPID; N ACETYLASPARTIC ACID; PRESENILIN;

AGING; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN SIZE; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; GENE; HIPPOCAMPUS; MALE; MOUSE; MULTIVARIATE ANALYSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRESENILIN GENE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TRANSGENIC MOUSE;

EID: 47049101371     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2007.03.002     Document Type: Article

References (37)

1. Ackl N., Ising M., Schreiber Y.A., Atiya M., Sonntag A., and Auer D.P. Hippocampal metabolic abnormalities in mild cognitive impairment and Alzheimer's disease. Neurosci. Lett. 384 (2005) 23-28
2. Borchelt D.R., Ratovitski T., van Lare J., Lee M.K., Gonzales V., Jenkins N.A., Copeland N.G., Price D.L., and Sisodia S.S. Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron 19 (1997) 939-945
3. Codita A., Winblad B., and Mohammed A.H. Of mice and men: more neurobiology in dementia. Curr. Opin. Psychiatry 19 (2006) 555-563
4. Coimbra A., Williams D.S., and Hostetler E.D. The role of MRI and PET/SPECT in Alzheimer's disease. Curr. Top. Med. Chem. 6 (2006) 629-647
5. Dedeoglu A., Choi J.K., Cormier K., Kowall N.W., and Jenkins B.G. Magnetic resonance spectroscopic analysis of Alzheimer's disease mouse brain that express mutant human APP shows altered neurochemical profile. Brain Res. 1012 (2004) 60-65
6. Duff K., Eckman C., Zehr C., Yu X., Prada C.M., Perez-tur J., Hutton M., Buee L., Harigaya Y., Yager D., Morgan D., Gordon M.N., Holcomb L., Refolo L., Zenk B., Hardy J., and Younkin S. Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. Nature 383 (1996) 710-713
7. Frederick B.D., Lyoo I.K., Satlin A., Ahn K.H., Kim M.J., Yurgelun-Todd D.A., Cohen B.M., and Renshaw P.F. In vivo proton magnetic resonance spectroscopy of the temporal lobe in Alzheimer's disease. Prog. Neuropsychopharmacol. Biol. Psychiatry 28 (2004) 1313-1322
8. Games D., Adams D., Alessandrini R., Barbour R., Berthelette P., Blackwell C., Carr T., Clemens J., Donaldson T., Gillespie F., et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 373 (1995) 523-527
9. Games D., Buttini M., Kobayashi D., Schenk D., and Seubert P. Mice as models: transgenic approaches and Alzheimer's disease. J. Alzheimers Dis. 9 (2006) 133-149
10. Godbolt A.K., Waldman A.D., MacManus D.G., Schott J.M., Frost C., Cipolotti L., Fox N.C., and Rossor M.N. MRS shows abnormalities before symptoms in familial Alzheimer disease. Neurology 66 (2006) 718-722
11. Griffith V.T. Diagnose and treat mild to moderate Alzheimer's disease. Nurse Pract. 27 (2002) 13-25 (26 quiz)
12. Higgins G.A., and Jacobsen H. Transgenic mouse models of Alzheimer's disease: phenotype and application. Behav. Pharmacol. 14 (2003) 419-438
13. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., Yang F., and Cole G. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274 (1996) 99-102
14. Jones R.S., and Waldman A.D. 1H-MRS evaluation of metabolism in Alzheimer's disease and vascular dementia. Neurol. Res. 26 (2004) 488-495
15. Kobayashi D.T., and Chen K.S. Behavioral phenotypes of amyloid-based genetically modified mouse models of Alzheimer's disease. Genes Brain Behav. 4 (2005) 173-196
16. Lavebratt C., Trifunovski A., Persson A.S., Wang F.H., Klason T., Ohman I., Josephsson A., Olson L., Spenger C., and Schalling M. Carbamazepine protects against megencephaly and abnormal expression of BDNF and Nogo signaling components in the mceph/mceph mouse. Neurobiol. Dis. 24 (2006) 374-383
17. Lewis J., Dickson D.W., Lin W.L., Chisholm L., Corral A., Jones G., Yen S.H., Sahara N., Skipper L., Yager D., Eckman C., Hardy J., Hutton M., and McGowan E. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 293 (2001) 1487-1491
18. Luxenberg J.S., Haxby J.V., Creasey H., Sundaram M., and Rapoport S.I. Rate of ventricular enlargement in dementia of the Alzheimer type correlates with rate of neuropsychological deterioration. Neurology 37 (1987) 1135-1140
19. Marjanska M., Curran G.L., Wengenack T.M., Henry P.G., Bliss R.L., Poduslo J.F., Jack Jr. C.R., Ugurbil K., and Garwood M. Monitoring disease progression in transgenic mouse models of Alzheimer's disease with proton magnetic resonance spectroscopy. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 11906-11910
20. Moats R.A., Ernst T., Shonk T.K., and Ross B.D. Abnormal cerebral metabolite concentrations in patients with probable Alzheimer disease. Magn. Reson. Med. 32 (1994) 110-115
21. Oberg J., Lindberg M., Andersson A., Klason T., Wang F., and Spenger C. Alzheimer's & Dementia. J. Alzheimer's Assoc. 2 3 (2006) 325
22. Oddo S., Caccamo A., Shepherd J.D., Murphy M.P., Golde T.E., Kayed R., Metherate R., Mattson M.P., Akbari Y., and LaFerla F.M. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 39 (2003) 409-421
23. Oz G., Tkac I., Charnas L.R., Choi I.Y., Bjoraker K.J., Shapiro E.G., and Gruetter R. Assessment of adrenoleukodystrophy lesions by high field MRS in non-sedated pediatric patients. Neurology 64 (2005) 434-441
24. Penet M.F., Laigle C., Fur Y.L., Confort-Gouny S., Heurteaux C., Cozzone P.J., and Viola A. In vivo characterization of brain morphometric and metabolic endophenotypes in three inbred strains of mice using magnetic resonance techniques. Behav. Genet. 36 (2006) 732-744
25. Provencher S.W. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn. Reson. Med. 30 (1993) 672-679
26. Provencher S.W. Automatic quantitation of localized in vivo 1H spectra with LCModel. NMR Biomed. 14 (2001) 260-264
27. Redwine J.M., Kosofsky B., Jacobs R.E., Games D., Reilly J.F., Morrison J.H., Young W.G., and Bloom F.E. Dentate gyrus volume is reduced before onset of plaque formation in PDAPP mice: a magnetic resonance microscopy and stereologic analysis. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 1381-1386
28. Reilly J.F., Games D., Rydel R.E., Freedman S., Schenk D., Young W.G., Morrison J.H., and Bloom F.E. Amyloid deposition in the hippocampus and entorhinal cortex: quantitative analysis of a transgenic mouse model. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 4837-4842
29. Ross B.D. Biochemical considerations in 1H spectroscopy. Glutamate and glutamine; myo-inositol and related metabolites. NMR Biomed. 4 (1991) 59-63
30. Rudkin T.M., and Arnold D.L. Proton magnetic resonance spectroscopy for the diagnosis and management of cerebral disorders. Arch. Neurol. 56 (1999) 919-926
31. Schuff N., Amend D., Ezekiel F., Steinman S.K., Tanabe J., Norman D., Jagust W., Kramer J.H., Mastrianni J.A., Fein G., and Weiner M.W. Changes of hippocampal N-acetyl aspartate and volume in Alzheimer's disease. A proton MR spectroscopic imaging and MRI study. Neurology 49 (1997) 1513-1521
32. Sunnemark D., Eltayeb S., Wallstrom E., Appelsved L., Malmberg A., Lassmann H., Ericsson-Dahlstrand A., Piehl F., and Olsson T. Differential expression of the chemokine receptors CX3CR1 and CCR1 by microglia and macrophages in myelin-oligodendrocyte-glycoprotein-induced experimental autoimmune encephalomyelitis. Brain Pathol. 13 (2003) 617-629
33. Thompson P.M., Hayashi K.M., de Zubicaray G., Janke A.L., Rose S.E., Semple J., Herman D., Hong M.S., Dittmer S.S., Doddrell D.M., and Toga A.W. Dynamics of gray matter loss in Alzheimer's disease. J. Neurosci. 23 (2003) 994-1005
34. Valenzuela M.J., and Sachdev P. Magnetic resonance spectroscopy in AD. Neurology 56 (2001) 592-598
35. Van Dam D., and De Deyn P.P. Drug discovery in dementia: the role of rodent models. Nat. Rev. Drug Discov. 5 (2006) 956-970
36. von Kienlin M., Kunnecke B., Metzger F., Steiner G., Richards J.G., Ozmen L., Jacobsen H., and Loetscher H. Altered metabolic profile in the frontal cortex of PS2APP transgenic mice, monitored throughout their life span. Neurobiol. Dis. 18 (2005) 32-39
37. Zhu X., Schuff N., Kornak J., Soher B., Yaffe K., Kramer J.H., Ezekiel F., Miller B.L., Jagust W.J., and Weiner M.W. Effects of Alzheimer disease on fronto-parietal brain N-acetyl aspartate and myo-inositol using magnetic resonance spectroscopic imaging. Alzheimer Dis. Assoc. Disord. 20 (2006) 77-85